Skip to main content
Premium Trial:

Request an Annual Quote

Making a Mark

Nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program have influenced patient care, a new analysis has found.

Researchers led by Fred Hutchinson Cancer Research Center's Joseph Unger analyzed the effects of 182 trials in which the SWOG Cancer Research Network participated between January 1980 and June 2017. The SWOG Cancer Research Network is part of NCI's Clinical Trial Network (NCTN), which aims to identify new cancer treatments.

As they report in JAMA Network Open, the researchers, who are affiliated with SWOG, found that 82 of those trials, or about 45 percent, were associated with guideline care or new drug indications. In particular, they report that 38.5 percent of the trials influenced National Comprehensive Cancer Network guidelines, 3.3 percent influenced new drug approvals by the Food and Drug Administration, and 3.3 percent influenced both guidelines and drug approvals.

The researchers note that trials with both positive and negative results were influential, as about 42 percent of the practice-influencing trials were ones with negative results.

"Federally funded cancer treatment trials fill an important gap in clinical research by seeking answers to treatment questions that might not otherwise be explored," James Doroshow, the director of NCI's Division of Cancer Treatment and Diagnosis, which oversees the NCTN, says in a statement. "This study sheds light on the critical role these trials have in guiding clinical cancer treatment, whether the findings from the trials are positive or negative."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.